Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › small lymphocytic lymphoma

Small lymphocytic lymphoma

Part of Leukemia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for small lymphocytic lymphoma

47 trials tracked for small lymphocytic lymphoma: 10 in phase 3 or 4 and 7 with published results. The most-cited published study has 411 citations.

47Trials tracked
10Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 10 Phase 2 34 Phase 1 3
  1. Phase 3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed · 411 cited
  2. Phase 3 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Completed · 341 cited
  3. Phase 3 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL Completed · 273 cited
  4. Phase 3 Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed · 272 cited
  5. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 112 cited
  6. Phase 3 A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Completed · 83 cited
Show 41 more trials
  1. Phase 3 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Completed · 9 cited
  2. Phase 3 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed
  3. Phase 3 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 Completed
  4. Phase 3 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed
  5. Phase 2 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed
  6. Phase 2 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Completed
  7. Phase 2 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed
  8. Phase 2 Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Completed
  9. Phase 2 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed
  10. Phase 2 Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Completed
  11. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  12. Phase 2 A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Completed
  13. Phase 2 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Completed
  14. Phase 2 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Completed
  15. Phase 2 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Completed
  16. Phase 2 Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Completed
  17. Phase 2 A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Completed
  18. Phase 2 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed
  19. Phase 2 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Completed
  20. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  21. Phase 2 Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Completed
  22. Phase 2 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia Completed
  23. Phase 2 Imexon for Relapsed Follicular and Aggressive Lymphomas Completed
  24. Phase 2 Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  25. Phase 2 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Completed
  26. Phase 2 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Completed
  27. Phase 2 Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL Completed
  28. Phase 2 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
  29. Phase 2 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Completed
  30. Phase 2 Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Completed
  31. Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed
  32. Phase 2 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Completed
  33. Phase 2 Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed
  34. Phase 2 Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Completed
  35. Phase 2 Tandem Auto-Allo Transplant for Lymphoma Completed
  36. Phase 2 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Completed
  37. Phase 2 Safety of PCI-32765 in Chronic Lymphocytic Leukemia Completed
  38. Phase 2 Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  39. Phase 1 Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) Completed
  40. Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) Completed
  41. Phase 1 Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Completed

Showing the 47 most-cited and recently-updated of 47 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Small lymphocytic lymphoma: what the trials found

Ibrutinib has demonstrated significant efficacy in several trials. Patients treated with Ibrutinib showed a Progression Free Survival (PFS) of 106.9 months versus 15.0 months (p<0.0001) 3, and another trial reported a PFS of 65.12 months versus 14.32 months (p<0.0001) 5. Additionally, Ibrutinib showed an Overall Response Rate (ORR) of 91.2% vs 36.8% 3 and 82.4% vs 35.3% 4, with a significant proportion of patients achieving sustained hemoglobin improvement 4 and MRD-negative responses 5. In a specific MRD cohort, Ibrutinib showed a Complete Response Rate (CRR) of 58.1% vs 57.2% (p<0.0001) 21.

Zanubrutinib demonstrated an ORR of 83.5% to 86.2% compared to 74.2% to 75.7% (p<0.0001) and a PFS of 34.2 months 7.

Other established interventions include Fludarabine 19, where some patients were able to discontinue prophylactic Tacrolimus 20, and IPI-145 9. While Rituximab was evaluated in two trials, results were mixed: one trial showed a significant improvement in progression-free survival (p<0.0001) 10, while another did not show a statistically significant difference in event-free survival (p=0.26) 8. Ofatumumab showed an ORR of 4.1% vs 42.6% (p<0.0001) and a PFS of 8.1 months, but did not reach statistical significance for overall survival (p=0.1653) 11.

Duvelisib was evaluated in a Phase 3 trial 2, and Cyclosporine was also established in the literature 6.

Recent results — preliminary, needs further review

  • BGB-10188 is currently under investigation in a Phase 2 trial 1.

For the clinician treating this condition

  • Ibrutinib shows robust and consistent evidence for improved Progression Free Survival (PFS) and Overall Response Rate (ORR) across multiple trials.
  • Zanubrutinib demonstrated statistically significant improvements in ORR compared to the control group.
  • Rituximab results are inconsistent regarding event-free survival, though it showed significant improvement in progression-free survival in one specific study.

AI synthesis of 14 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Oncology RCT
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Apr 28, 2026

Research across Leukemia

Related studies from across the Leukemia family.

Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Oncology RCT
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Blood Jun 20, 2026
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
Drug Pipeline Meta-analysis
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
medRxiv Jun 4, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age
Oncology Phase II
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Blood Apr 13, 2026
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Hematology
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome.
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.
Frontiers Apr 1, 2026